BIOLINERX LTD/S (BLRX) Receives “Buy” Rating from Oppenheimer

Share on StockTwits

Oppenheimer reaffirmed their buy rating on shares of BIOLINERX LTD/S (NASDAQ:BLRX) in a research note published on Tuesday.

Several other equities research analysts also recently commented on BLRX. Maxim Group set a $2.00 price objective on BIOLINERX LTD/S and gave the stock a buy rating in a report on Wednesday, December 12th. HC Wainwright set a $4.00 price objective on BIOLINERX LTD/S and gave the stock a buy rating in a report on Tuesday, December 11th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $2.50.

NASDAQ BLRX opened at $0.46 on Tuesday. BIOLINERX LTD/S has a one year low of $0.38 and a one year high of $1.84. The stock has a market capitalization of $46.79 million, a P/E ratio of -1.71 and a beta of 1.70.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Securities LLC bought a new stake in BIOLINERX LTD/S in the 4th quarter worth about $25,000. Menta Capital LLC bought a new stake in BIOLINERX LTD/S in the 4th quarter worth about $33,000. Finally, ETF Managers Group LLC increased its holdings in BIOLINERX LTD/S by 79.4% in the 4th quarter. ETF Managers Group LLC now owns 375,909 shares of the biotechnology company’s stock worth $164,000 after buying an additional 166,386 shares in the last quarter. Institutional investors own 33.79% of the company’s stock.

BIOLINERX LTD/S Company Profile

BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

See Also: How is a Moving Average Calculated?

Receive News & Ratings for BIOLINERX LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLINERX LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

North American Palladium  Upgraded at ValuEngine
North American Palladium Upgraded at ValuEngine
ValuEngine Lowers Investors Real Estate Trust Reit  to Hold
ValuEngine Lowers Investors Real Estate Trust Reit to Hold
The GEO Group  Cut to Sell at ValuEngine
The GEO Group Cut to Sell at ValuEngine
B&G Foods  Downgraded by ValuEngine
B&G Foods Downgraded by ValuEngine
ValuEngine Upgrades Iamgold  to Hold
ValuEngine Upgrades Iamgold to Hold
US Ecology  Upgraded by ValuEngine to “Buy”
US Ecology Upgraded by ValuEngine to “Buy”


 
© 2006-2019 Zolmax.